Nivolumab-ipilimumab displays potential in malignant pleural mesothelioma
24 Sep 2020
byRoshini Claire Anthony
For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.